Life-expectancy for individuals with younger-onset disease is on average of 16 years shorter compared to people without diabetes, and

stay healthy…
Life-expectancy for individuals with younger-onset disease is on average of 16 years shorter compared to people without diabetes, and
FDA approves Jynarque (tolvaptan) to slow kidney function decline in rapidly progressing autosomal dominant polycystic kidney disease ADPKD. ADPKD is